Darunavir (Prezista)

Published August 09, 2006; Updated October 19, 2011
Susa Coffey, MD
Selected Reference
9. Cahn P, Fourie J, Grinsztejn B, et al. Efficacy and safety at 48 weeks of once-daily vs twice-daily DRV/r in treatment-experienced HIV-1+ patients with no DRV resistance associated mutations: the ODIN Trial. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, California. Abstract 57.